Imperial spinout NK:IO awarded £1.6M Innovate UK New Cancer Therapeutics grant for development of pioneering NK cell therapy

NK:IO, a leader in NK cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumors, today announced it has been awarded £1.6M in grant funding from Innovate UK’s New Cancer Therapeutics program. The funding will support preclinical development, including development of a manufacturing process in collaboration with the Cell and Gene Therapy Catapult, whose mission is to support the UK’s cell and gene therapy industry.

NK:IO is based on pioneering discoveries in NK cell biology from Hugh J M Brady, Professor of Immunology, and Matt Fuchter, Professor of Chemistry, at Imperial College. NK:IO is exploiting these discoveries in its unique platform which activates blood stem cell progenitors to yield industry-leading NK cell tumor-killing potency and very high yield cell production, which it believes will be transformative in cancer cell therapy. In addition, this platform enables efficient engineering of progenitor cells to produce next-generation NK cells for further increases in potency or tumor targeting, which NK:IO is progressing for certain hard to treat tumor subtypes.

The company was founded in December 2020 by Hugh J M Brady, Matt Fuchter, and Mike Romanos, an experienced industry executive and entrepreneur. The Board is chaired by Keith Thompson CBE, former CEO of the UK’s Cell and Gene Therapy Catapult. The company’s first indication targeted will be ovarian cancer, in collaboration with Prof. Iain McNeish, Professor of Oncology at Imperial College, Director of the Ovarian Cancer Action Research Centre and a leading expert in the field.

We are very excited by the potential of NK:IO’s platform to address unmet needs in cancer therapy and delighted to receive grant funding from this highly competitive new Innovate UK program. The funding will directly support our collaboration with the Cell and Gene Therapy Catapult in a program of development work to scale our products and make them clinic-ready for our first clinical application in ovarian cancer.”

Mike Romanos, Co-Founder and Interim CEO, NK:IO

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NK:IO Limited. (2023, July 11). Imperial spinout NK:IO awarded £1.6M Innovate UK New Cancer Therapeutics grant for development of pioneering NK cell therapy. News-Medical. Retrieved on March 03, 2024 from https://www.news-medical.net/news/20230711/Imperial-spinout-NKIO-awarded-c2a316M-Innovate-UK-New-Cancer-Therapeutics-grant-for-development-of-pioneering-NK-cell-therapy.aspx.

  • MLA

    NK:IO Limited. "Imperial spinout NK:IO awarded £1.6M Innovate UK New Cancer Therapeutics grant for development of pioneering NK cell therapy". News-Medical. 03 March 2024. <https://www.news-medical.net/news/20230711/Imperial-spinout-NKIO-awarded-c2a316M-Innovate-UK-New-Cancer-Therapeutics-grant-for-development-of-pioneering-NK-cell-therapy.aspx>.

  • Chicago

    NK:IO Limited. "Imperial spinout NK:IO awarded £1.6M Innovate UK New Cancer Therapeutics grant for development of pioneering NK cell therapy". News-Medical. https://www.news-medical.net/news/20230711/Imperial-spinout-NKIO-awarded-c2a316M-Innovate-UK-New-Cancer-Therapeutics-grant-for-development-of-pioneering-NK-cell-therapy.aspx. (accessed March 03, 2024).

  • Harvard

    NK:IO Limited. 2023. Imperial spinout NK:IO awarded £1.6M Innovate UK New Cancer Therapeutics grant for development of pioneering NK cell therapy. News-Medical, viewed 03 March 2024, https://www.news-medical.net/news/20230711/Imperial-spinout-NKIO-awarded-c2a316M-Innovate-UK-New-Cancer-Therapeutics-grant-for-development-of-pioneering-NK-cell-therapy.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post